Modality
Bispecific Ab
MOA
CDK2i
Target
CD47
Pathway
Checkpoint
SCLC
Development Pipeline
Preclinical
~Sep 2016
→ ~Dec 2017
Phase 1
~Mar 2018
→ ~Jun 2019
Phase 2
~Sep 2019
→ ~Dec 2020
Phase 3
~Mar 2021
→ ~Jun 2022
NDA/BLA
Sep 2022
→ Nov 2028
NDA/BLACurrent
NCT03311541
1,958 pts·SCLC
2022-09→2028-11·Completed
1,958 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-11-012.6y awayPh3 Readout· SCLC
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2028-11-01 · 2.6y away
SCLC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03311541 | NDA/BLA | SCLC | Completed | 1958 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 |